Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling.

Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, Leonard WJ, Broxmeyer HE.

J Exp Med. 2000 Sep 4;192(5):719-28.

3.

Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway.

Santos SC, Lacronique V, Bouchaert I, Monni R, Bernard O, Gisselbrecht S, Gouilleux F.

Oncogene. 2001 Apr 19;20(17):2080-90.

4.

Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.

Drexler HG.

Leukemia. 1996 Apr;10(4):588-99. Review.

PMID:
8618433
5.
6.

Growth hormone-induced tyrosyl phosphorylation and deoxyribonucleic acid binding activity of Stat5A and Stat5B.

Smit LS, Vanderkuur JA, Stimage A, Han Y, Luo G, Yu-Lee LY, Schwartz J, Carter-Su C.

Endocrinology. 1997 Aug;138(8):3426-34.

PMID:
9231797
8.

STAT signaling in ischemic heart: a role of STAT5A in ischemic preconditioning.

Yamaura G, Turoczi T, Yamamoto F, Siddqui MA, Maulik N, Das DK.

Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H476-82.

9.

The functional role of the JAK-STAT pathway in post-infarction remodeling.

El-Adawi H, Deng L, Tramontano A, Smith S, Mascareno E, Ganguly K, Castillo R, El-Sherif N.

Cardiovasc Res. 2003 Jan;57(1):129-38.

10.
11.

Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).

Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T.

J Biol Chem. 2003 Aug 29;278(35):32892-8. Epub 2003 Jun 18.

12.

Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells.

Nosaka T, Kitamura T.

Int J Hematol. 2000 Jun;71(4):309-19. Review. Erratum in: Int J Hematol 2000 Jul;72(1):124.

PMID:
10905049
13.

JAK/STAT-dependent gene regulation by cytokines.

Hebenstreit D, Horejs-Hoeck J, Duschl A.

Drug News Perspect. 2005 May;18(4):243-9. Review.

PMID:
16034480
14.

Signal transduction pathways induced by GM-CSF in microglia: significance in the control of proliferation.

Liva SM, Kahn MA, Dopp JM, de Vellis J.

Glia. 1999 Jun;26(4):344-52.

PMID:
10383053
15.

Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.

Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.

Clin Cancer Res. 2003 Jun;9(6):2140-50.

16.
17.

The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.

Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W.

Blood. 2003 Feb 15;101(4):1494-504. Epub 2002 Oct 24.

18.

Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor.

Tse KF, Novelli E, Civin CI, Bohmer FD, Small D.

Leukemia. 2001 Jul;15(7):1001-10.

PMID:
11455967
19.

Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway.

Okutani Y, Kitanaka A, Tanaka T, Kamano H, Ohnishi H, Kubota Y, Ishida T, Takahara J.

Oncogene. 2001 Oct 4;20(45):6643-50.

20.

Essential role of Stat5 for IL-5-dependent IgH switch recombination in mouse B cells.

Horikawa K, Kaku H, Nakajima H, Davey HW, Hennighausen L, Iwamoto I, Yasue T, Kariyone A, Takatsu K.

J Immunol. 2001 Nov 1;167(9):5018-26.

Items per page

Supplemental Content

Write to the Help Desk